Whole genome sequence analyses of Indonesian isolates SARS‐CoV‐2 variants and their clinical manifestations
Elnora Listianto Lie(1), Tedi Dwi Fauzi Hermawan(2), Kholis Abdurachim Audah(3*)
(1) Department of Biomedical Engineering, Faculty of Life Sciences and Technology, Swiss German University (SGU), Tangerang 15143, Indonesia
(2) Department of Biomedical Engineering, Faculty of Life Sciences and Technology, Swiss German University (SGU), Tangerang 15143, Indonesia
(3) Department of Biomedical Engineering, Faculty of Life Sciences and Technology, Swiss German University (SGU), Tangerang 15143, Indonesia
(*) Corresponding Author
Abstract
The SARS‐CoV‐2 virus has been the cause of the global pandemic since the end of 2019. Since then, the virus has mutated to create different types of variants with numerous effects on those infected. This has complicated human intervention for prevention. Indonesia was heavily affected by the pandemic, specifically from May to August 2021, and as a country has recorded many distinct isolates. Thus, characterization of the virus strains from Indonesia is important. GISAID, NCBI BLAST, and MAFFT version 7 were used. There were 9,488 isolates in Indonesia as of November 2021, with the majority including the Delta variant. While most of the isolates have mutations common to those from other countries, there are some atypical ones, such as mutation V1264L in the Delta variant that was suspected to play a role in worsening the pandemic. The Delta variant had the most mutations in the spike protein when compared to the Alpha and Beta variants, giving it important roles in infectivity and vigorous entry into cells, with some general clinical manifestations like fever and sore throat; however, the severity of the Delta variant is attributable to its rapid growth. This is why, from May to November 2021 in Indonesia, cases of the Delta variant rocketed, unlike the other variants.
Keywords
References
Acro Biosystems. 2021. Nucleocapsid protein (D63G, R203M, G215C, D377Y), His Tag. URL https://www.acrobiosystems.com/P4135SARSCoV2Nucleocapsidprotein%28D63GR203MG215CD377Y%29HisTag.html.
Aleem A, Akbar Samad AB, Vaqar S. 2021. Emerging Variants of SARSCoV2 And Novel Therapeutics Against Coronavirus (COVID19). Treasure Island (FL): StatPearls Publishing.
Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M. 2020. COVID2019: The role of the nsp2 and nsp3 in its pathogenesis. J. Med. Virol. 92(6):584–588. doi:10.1002/jmv.25719.
Azad GK, Khan PK. 2021. Variations in Orf3a protein of SARSCoV2 alter its structure and function. Biochem. Biophys. Reports 26:100933. doi:10.1016/j.bbrep.2021.100933.
Bakhshandeh B, Jahanafrooz Z, Abbasi A, Goli MB, Sadeghi M, Mottaqi MS, Zamani M. 2021. Mutations in SARSCoV2; Consequences in structure, function, and pathogenicity of the virus. Microb. Pathog. 154:104831. doi:10.1016/j.micpath.2021.104831.
Banerjee S, Seal S, Dey R, Mondal KK, Bhattacharjee P. 2021. Mutational spectra of SARSCoV2 ORF1ab polyprotein and signature mutations in the United States of America. J. Med. Virol. 93(3):1428–1435. doi:10.1002/jmv.26417.
Banoun H. 2021. Evolution of SARSCoV2: Review of Mutations, Role of the Host Immune System. Nephron 145(4):1–12. doi:10.1159/000515417.
Cahyani I, Putro EW, Ridwanuloh AM, Wibowo S, Hariyatun H, Syahputra G, Akbariani G, Utomo AR, Ilyas M, Loose M, Kusharyoto W, Susanti S. 2022. Genome Profiling of SARSCoV2 in Indonesia, ASEAN and the Neighbouring East Asian Countries: Features, Challenges and Achievements. Viruses 14(4):778. doi:10.3390/v14040778.
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. 2020. Features, Evaluation and Treatment Coronavirus (COVID19). Treasure Island (FL): StatPearls Publishing. URL https://www.ncbi.nlm.nih.gov/boo ks/NBK554776.
CDC. 2021. Symptoms of COVID19. URL https://www.cdc.gov/coronavirus/2019ncov/s ymptomstesting/symptoms.html. Accessed: 2022 Jul 24.
Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, Rakshit P, Singh S, Abraham P, Panda S. 2021. Sarscov2 spike mutations, l452r, t478k, e484q and p681r, in the second wave of covid19 in Maharashtra, India. Microorganisms 9(7):1542. doi:10.3390/microorganisms9071542.
Chohan F, Ishak A, Alderette T, Rad P, Michel G. 2021. Clinical Presentation of a COVID19 Delta Variant Patient: Case Report and Literature Review. Cureus p. e18603. doi:10.7759/cureus.18603.
Chowdhury S, Bappy MH, Chowdhury S, Chowdhury MS, Chowdhury NS. 2021. Current Review of Delta Variant of SARSCoV2. Eur. J. Med. Heal. Sci. 3(6):23–29. doi:10.24018/ejmed.2021.3.6.1120.
Duncan MJ, Shin JS, Abraham SN. 2002. Microbial entry through caveolae: Variations on a theme. Cell. Microbiol. 4(12):783–791. doi:10.1046/j.1462 5822.2002.00230.x.
European Centre for Disease Prevention and Control. 2021. SARSCoV2 variants of concern as of 3 December 2021. URL https://www.ecdc.europa.eu/en/ covid19/variantsconcern. Accessed: 2021 Dec 6.
Ferreira IA, Kemp SA, Datir R, Saito A, Meng B, Rakshit P, TakaoriKondo A, Kosugi Y, Uriu K, Kimura I, Shirakawa K, Abdullahi A, Agarwal A, Ozono S, Tokunaga K, Sato K, Gupta RK. 2021. SARSCoV2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion. J. Infect. Dis. 224(6):989–994. doi:10.1093/infdis/jiab368.
Gulland A. 2021. Beta variant: what we know about symptoms, vaccine protection and cases in the UK and France. Telegr. UK. URL https://www.telegraph.co.uk/globalhealth/scienc eanddisease/betavariantknowsymptomsvaccine protectioncasesukfrance/. Accessed: 2022 Aug 4.
Gupta N, Kaur H, Yadav PD, Mukhopadhyay L, Sahay RR, Kumar A, Nyayanit DA, Shete AM, Patil S, Majumdar T, Rana S, Gupta S, Narayan J, Vijay N, Barde P, Nataraj G, Amrutha Kumari B, Kumari MP, Biswas D, Iravane J, Raut S, Dutta S, Devi S, Barua P, Gupta P, Borkakoty B, Kalita D, Dhingra K, Fomda B, Joshi Y, Goyal K, John R, Munivenkatappa A, Dhodapkar R, Pandit P, Devi S, Dudhmal M, Kinariwala D, Khandelwal N, Tiwari YK, Khatri PK, Gupta A, Khatri H, Malhotra B, Nagasundaram M, Dar L, Sheikh N, Shastri J, Aggarwal N, Abraham P. 2021. Clinical characterization and genomic analysis of samples from COVID19 breakthrough infections during the second wave among the various states of India. Viruses 13(9):1782. doi:10.3390/v13091782.
Guruprasad L. 2021. Human SARS CoV2 spike protein mutations. Proteins Struct. Funct. Bioinforma. 89(5):569–576. doi:10.1002/prot.26042.
Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A, Peacock SJ, Robertson DL. 2021. SARSCoV2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19(7):409–424. doi:10.1038/s41579 021005730.
Hui EKW, Nayak DP. 2002. Role of G protein and protein kinase signalling in influenza virus budding in MDCK cells. J. Gen. Virol. 83(12):3055–3066. doi:10.1099/0022131783123055.
Hussman JP. 2020. Cellular and Molecular Pathways of COVID19 and Potential Points of Therapeutic Intervention. Front. Pharmacol. 11:1169. doi:10.3389/fphar.2020.01169.
Jakhmola S, Indari O, Kashyap D, Varshney N, Das A, Manivannan E, Jha HC. 2021. Mutational analysis of structural proteins of SARSCoV2. Heliyon 7(3):e06572. doi:10.1016/j.heliyon.2021.e06572.
Kannan SR, Spratt AN, Cohen AR, Naqvi SH, Chand HS, Quinn TP, Lorson CL, Byrareddy SN, Singh K. 2021. Evolutionary analysis of the Delta and Delta Plus variants of the SARSCoV2 viruses. J. Autoimmun. 124:102715. doi:10.1016/j.jaut.2021.102715.
Karyono DR, Wicaksana AL. 2020. Current prevalence, characteristics, and comorbidities of patients with COVID19 in Indonesia. J. Community Empower. Heal. 3(2):77. doi:10.22146/jcoemph.57325.
Khailany RA, Safdar M, Ozaslan M. 2020. Genomic characterization of a novel SARSCoV2. Gene Rep. 19:100682. doi:10.1016/j.genrep.2020.100682.
Khateeb J, Li Y, Zhang H. 2021. Emerging SARSCoV 2 variants of concern and potential intervention approaches. Crit. Care 25(1):1–8. doi:10.1186/s13054 02103662x.
Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Foley B, Giorgi EE, Bhattacharya T, Parker MD, Partridge DG, Evans CM, Freeman TM, de Silva TI, LaBranche CC, Montefiori DC. 2020. Spike mutation pipeline reveals the emergence of a more transmissible form of SARSCoV2. bioRxiv 2020.04.29.069054 doi:10.1101/2020.04.29.069054.
Lee Y, Min P, Lee S, Kim SW. 2020. Prevalence and duration of acute loss of smell or taste in COVID 19 patients. J. Korean Med. Sci. 35(18):e174. doi:10.3346/JKMS.2020.35.E174.
Li B, Deng A, Li KB, Hu Y, Li Z, Xiong Q, Liu Z, Guo Q, Zou L, Zhang H, Zhang M, Ouyang F, Su J, Su W, Xu J, Lin H, Sun J, Peng J, Jiang H, Lu J. 2021. Viral infection and Transmission in a large welltraced outbreak caused by the Delta SARSCoV2 variant. Nat. Commun. 13(1):460. doi:10.1101/2021.07.07.21260122.
Lubinski B, Fernandes MH, Frazier L, Tang T, Daniel S, Diel DG, Jaimes JA, Whittaker GR. 2022. Functional evaluation of the P681H mutation on the proteolytic activation of the SARSCoV2 variant B.1.1.7 (Alpha) spike. iScience 25(1):103589. doi:10.1016/j.isci.2021.103589.
LunaMuschi A, Borges IC, de Faria E, Barboza AS, Maia FL, Leme MD, Guedes AR, MendesCorrea MC, Kallas EG, Segurado AC, Duarte AJ, Lazari CS, Andrade PS, Sales FC, Claro IM, Sabino EC, Levin AS, Costa SF. 2022. Clinical features of COVID19 by SARSCoV2 Gamma variant: A prospective cohort study of vaccinated and unvaccinated healthcare workers. J. Infect. 84(2):248–288. doi:10.1016/j.jinf.2021.09.005.
Meng B, Kemp SA, Papa G, Datir R, Ferreira IA, Marelli S, Harvey WT, Lytras S, Mohamed A, Gallo G. 2021. Recurrent emergence of SARSCoV2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep. 35(13):109292. doi:10.1016/j.celrep.2021.109292.
Mohammadi M, Shayestehpour M, Mirzaei H. 2021. The impact of spike mutated variants of SARSCoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Brazilian J. Infect. Dis. 25(4):101606. doi:10.1016/j.bjid.2021.101606.
Motozono C, Toyoda M, Zahradnik J, Ikeda T, Saito A, Tan TS, Ngare I, Nasser H, Kimura I, Uriu K, Kosugi Y, Torii S, Yonekawa A, Shimono N, Nagasaki Y, Minami R, Toya T, Sekiya N, Fukuhara T, Sato K. 2021. An Emerging SARSCoV2 Mutant Evades Cellular Immunity and Increases Infectivity. SSRN Electronic Journal doi:10.2139/ssrn.3827372.
Müller JA, Groß R, Conzelmann C, Krüger J, Merle U, Steinhart J, Weil T, Koepke L, Bozzo CP, Read C, Fois G, Eiseler T, Gehrmann J, van Vuuren J, Wessbecher IM, Frick M, Costa IG, Breunig M, Grüner B, Peters L, Schuster M, Liebau S, Seufferlein T, Stenger S, Stenzinger A, MacDonald PE, Kirchhoff F, Sparrer KM, Walther P, Lickert H, Barth TF, Wagner M, Münch J, Heller S, Kleger A. 2021. SARSCoV2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat. Metab. 3(2):149–165. doi:10.1038/s42255021003471.
Plante J, Plante K, Debbink K, Weaver S, Menachery V. 2021a. The Variant Gambit: COVID’s Next Move. Cell Host Microbe 29(4):508–515. doi:10.1016/j.chom.2021.02.020.
Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, Zhang X, Muruato AE, Zou J, FontesGarfias CR, Mirchandani D, Scharton D, Bilello JP, Ku Z, An Z, Kalveram B, Freiberg AN, Menachery VD, Xie X, Plante KS, Weaver SC, Shi PY. 2021b. Spike mutation D614G alters SARSCoV2 fitness. Nature 592(7852):116–121. doi:10.1038/s415860202895 3.
Pulakuntla S, Lokhande KB, Padmavathi P, Pal M, Swamy KV, Sadasivam J, Singh SA, Aramgam SL, Reddy VD. 2021. Mutational analysis in international isolates and drug repurposing against SARSCoV2 spike protein: molecular docking and simulation approach. VirusDisease 32(4):1–13. doi:10.1007/s13337021007204.
Rantam FA, Prakoeswa CRS, Tinduh D, Nugraha J, Susilowati H, Wijaya AY, Puspaningsih NNT, Puspitasari D, Husada D, Kurniati ND, Aryati A. 2021. Characterization of SARSCoV2 East Java isolate, Indonesia. F1000Research 10:480. doi:10.12688/f1000research.53137.1.
Rehman S, Mahmood T, Aziz E, Batool R. 2020. Identification of novel mutations in SARSCOV2 isolates from Turkey. Arch. Virol. 165(12):2937–2944. doi:10.1007/s00705020048300.
Rosa G, Brandtner D, Mancini P, Veneri C, Bonanno Ferraro G, Bonadonna L, Lucentini L, Suffredini E. 2021. Key SARSCoV2 Mutations of Alpha, Gamma, and Eta Variants Detected in Urban Wastewaters in Italy by LongRead Amplicon Sequencing Based on Nanopore Technology. Water 13(8):2503. doi:10.3390/w13182503.
Suratekar R, Ghosh P, Niesen MJM, Donadio G, Anand P, Soundararajan V, Venkatakrishnan AJ. 2022. High diversity in Delta variant across countries revealed by genomewide analysis of SARSCoV2 beyond the Spike protein. Mol. Syst. Biol. 18(2):e10673. doi:10.15252/msb.202110673.
Syed AM, Taha TY, Tabata T, Chen IP, Ciling A, Khalid MM, Sreekumar B, Chen PY, Hayashi JM, Soczek KM, Ott M, Doudna JA. 2021. Rapid assessment of SARSCoV2–;evolved variants using viruslike particles. Science 374(6575):1626– 1632. doi:10.1126/science.abl6184.
Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR. 2021. The Spike Proteins of SARSCoV2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccineelicited and Therapeutic Monoclonal Antibodies. bioRxiv .
The Franciscan Missionaries of Our Lady Health Systeml. 2021. Alpha Variant vs. Delta Variant – How Are the Symptoms Different? URL https: //health.fmolhs.org/body/covid19/alphavariantvs deltavarianthowarethesymptomsdifferent/.
Theoharides TC, Conti P. 2021. Be aware of SARSCoV 2 spike protein: There is more than meets the eye. J. Biol. Regul. Homeost. Agents 35(3):833–838.
Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z, Dong X, Zheng P. 2021. N501y mutation of spike protein in SARSCoV2 strengthens its binding to receptor ACE2. Elife 10:e69091. doi:10.7554/eLife.69091.
Ulfah M, Helianti I. 2021. Bioinformatic analysis of the whole genome sequences of SARSCoV2 from Indonesia. Iran J. Microbiol. 13(2):145–155. doi:10.18502/ijm.v13i2.5973.
Vassallo M, Manni S, Klotz C, Fabre R, Pini P, Blanchouin E, Sindt A, Lotte L, Dubertrand JM, Liguori S, Berkane N, Duval Y, Rolland F, Pradier C. 2021. Patients admitted for variant alpha COVID19 have poorer outcomes than those infected with the old strain. J. Clin. Med. 10(16):3550. doi:10.3390/jcm10163550.
Wruck W, Adjaye J. 2021. Detailed phylogenetic analysis tracks transmission of distinct SARSCOV2 variants from China and Europe to West Africa. Sci. Rep. 11(1):21108. doi:10.1038/s4159802100267w.
Yang XJ. 2021a. Delta1 variant of SARSCOV2 acquires spike V1264L and drives the pandemic in Indonesia, Singapore and Malaysia. Res. Sq. PREPRINT(Version 1). doi:10.21203/rs.3.rs 999390/v1.
Yang XJ. 2021b. SARSCOV2 δ variant drives the pandemic in India and Europe via two subvariants. medRxiv doi:10.1101/2021.10.16.21265096.
Yin C. 2020. Genotyping coronavirus SARSCoV2: methods and implications. Genomics 112(5):3588– 3596. doi:10.1016/j.ygeno.2020.04.016.
Zahra SA, Iddawela S, Pillai K, Choudhury RY, Harky A. 2020. Can symptoms of anosmia and dysgeusia be diagnostic for COVID19? Brain Behav. 10(11):e01839. doi:10.1002/brb3.1839.
Zhang J, Zhang J, Tao Z. 2022. Effect of Comorbid Diabetes on Clinical Characteristics of COVID19 Patients Infected by the WildType or Delta Variant of SARSCoV2. Front. Endocrinol. 13:861443. doi:10.3389/fendo.2022.861443.
Zheng YX, Wang L, Kong WS, Chen H, Wang XN, Meng Q, Zhang HN, Guo SJ, Jiang HW, Tao SC. 2021. Nsp2 has the potential to be a drug target revealed by global identification of SARSCoV2 Nsp2interacting proteins. Acta Biochim. Biophys. Sin. (Shanghai). 53(9):1134–1141. doi:10.1093/abbs/gmab088.
Zhou Z, Huang C, Zhou Z, Huang Z, Su L, Kang S, Chen X, Chen Q, He S, Rong X, Xiao F, Chen J, Chen S. 2021. Structural insight reveals SARSCoV2 ORF7a as an immunomodulating factor for human CD14+ monocytes. iScience 24(3):102187. doi:10.1016/j.isci.2021.102187.
DOI: https://doi.org/10.22146/ijbiotech.73783
Article Metrics
Abstract views : 3529 | views : 932 | views : 1192Refbacks
- There are currently no refbacks.
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.